EP
PTCT icon

Essential Partners’s PTC Therapeutics PTCT Stock Holding History

Essential Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9K Sell
171
-2,198
-93% -$159K 0.01% 1060
2026
Q1 		$161K Hold
2,369
– – 0.05% 320
2025
Q4 		$180K Buy
2,369
+59
+3% +$4.29K 0.06% 335
2025
Q3 		$142K Sell
2,310
-666
-22% -$34.7K 0.05% 379
2025
Q2 		$145K Buy
+2,976
New +$141K 0.06% 315

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Essential Partners's PTCT Position: Q2 2026 in Review

Essential Partners reduced its PTC Therapeutics (PTCT) stake by 93% in Q2 2026, selling an estimated $159K and leaving 171 shares worth $13.9K. The position accounts for 0.01% of the portfolio, ranked #1060.

Essential Partners first reported a position in PTCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $180K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Essential Partners held 171 shares of PTC Therapeutics worth $13.9K as of Q2 2026.
  • Essential Partners sold 2,198 PTC Therapeutics shares in Q2 2026, an estimated $159K.
  • PTC Therapeutics made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1060 holding.
  • Essential Partners first reported a position in PTC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's PTC Therapeutics position peaked at $180K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.